摘要
目的:联合应用天花粉蛋白(TCS)与重组人干扰素α—lb(rIFNα—lb),观察对肝癌的抑瘤作用及相互影响。方法:MTT比色法观察两药对不同肝细胞株的细胞毒;荷瘤裸鼠LCI—D20模型观察体内抑瘤作用。结果:体内抑瘤率分别为:TCS组48.5%,IFN组69.2%,联用组92.2%。TCS或IFN均有显著抑瘤作用(P<0.01)。联合用药组与单独用药组相比差异有统计学意义(P<0.05),协同抑瘤作用明显。TCS对不同肝细胞株有敏感性差异:TCS对正常肝细胞(L—02)、肝癌高低转移细胞株(MHCC97H、MHCC97L)的72h细胞毒作用IC_(50)分别为21.1μg/ml、6.9μg/ml、5.0μg/ml。联用IFN能提高L—02的IC_(50)、降低MHCC97H的IC_(50),进一步提高安全性。IFN能拮抗TCS的肝脏毒性、提高抑瘤效果;TCS亦能改善于扰素对血液系统的干扰。结论:TCS对肝癌抑瘤作用明显。联合用药既能减少不良反应、又能增强抑瘤作用。
Objective: To investigate the tumor inhibitory interaction of Trichosanthin and recombinant Interferon α -1b (IFNα- 1b) on human hepatocellular carcinoma. Methods: We use different cell lines and nude mice model bearing human hep-atocellular carcinoma (LCI -D20) to study this two drugs' interaction. Results: The tumor inhibition rate of Trichosanthin group,Interferon group and combined treatment group is 48. 5% ,69.2% and 92.2% in vivo,respectively.The tumor inhibito-ry effect of Trichosanthin or Interferon is significant difference compared with control (P< 0.01). The synergistic tumor in-hibitory effect is obvious by analysis of factorial experiment. There was significant difference between combined treatment group and individual treatment group (P < 0. 05). Trichosanthin has significant inhibitory effect and specific toxicity to liver cancer cells within treatment doses in vitro. Its IC50(inhibitory concentration 50%) of seventy two hours'treatment to normai cells(L -02),hepatocellular carcinoma clones with high(MHCC97H) and low(MHCC97L) metastatic potentials is 21. 1 μg/ ml、6.9μg/ml、5.0μg/ml respectively. IFN increases the IC50 of L-02 and decreases the IC50 of MHCC97H, thus increases security of trichosanthin. IFN decreases the hepatotoxicity and increases the tumor inhibitory effect of Trichosanthin which ameliorated the hematological disorder caused by IFN. Conclusion: Our results suggest that Trichosanthin has significant tumor inhibitory effect. Combined treatment with IFN enhances this effect and decreases side effect.
出处
《中国临床医学》
2003年第3期278-280,共3页
Chinese Journal of Clinical Medicine
基金
"973"国家重点基础研究发展规划基金(G1998051211)
上海市医学领先专业基金(983001)
